{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"ComPareNET","nct_id":"NCT05247905","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=comparenet-nct05247905. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive lutetium Lu 177 dotatate IV over 30 minutes on day 1 of each cycle. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples prior to registration, on days 1 and 29 of each cycle, during post-treatment follow-up, and at progressive disease, withdrawal or removal from study. Patients undergo PET prior to registration, and CT and/or MRI prior to registration and then every 3 months until progression.","label":"Arm I (lutetium Lu 177 dotatate)","type":"EXPERIMENTAL"},{"description":"Patients receive capecitabine PO BID days 1-14 of each cycle and temozolomide PO QD on days 10-14 of each cycle. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples prior to registration, on day 1 of each cycle, and at progressive disease, withdrawal, or removal from study. Patients undergo PET prior to registration, and CT and/or MRI prior to registration and then every 3 months until progression.","label":"Arm II (capecitabine, temozolomide)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2033-04-01","type":"ESTIMATED"},"conditions":["Metastatic Pancreatic Neuroendocrine Tumor","Unresectable Pancreatic Neuroendocrine Carcinoma"],"enrollment":{"count":31,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Lutetium Lu 177 Dotatate","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"},{"name":"Temozolomide","otherNames":[],"type":"DRUG"},{"name":"Quality-of-Life Assessment","otherNames":[],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-10-20","lead_sponsor":"Alliance for Clinical Trials in Oncology","official_title":"Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"Up to 8 years from randomization"}],"references":[],"start_date":{"date":"2023-02-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial","url":"https://clinicaltrials.gov/study/NCT05247905"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/comparenet-nct05247905"}